HOME >> BIOLOGY >> NEWS
Promising results in the battle against incurable ALS muscle disease

t the vascular endothelial growth factor (VEGF) plays a major role in this disease.

VEGF: a promising track to follow

VEGF is a signaling substance that controls the growth of blood vessels. To a large extent, a tissue in need of oxygen manufactures the protein, thereby developing new blood vessels so that the need for oxygen again diminishes. VEGF also helps neurons survive under stressful conditions. Last year, the work of Peter Carmeliet's team showed that persons who produce too little VEGF - due to certain variations in the gene that codes for VEGF - have a greater chance of developing ALS. Earlier this year, their research proved that gene therapy with the VEGF gene increased the life expectancy of ALS mice by 30%. But gene therapy is still a controversial method of treatment, whose path to the clinic can be quite long.

VEGF prolongs the life of ALS rats

So, investigation into a possible treatment using the VEGF protein has never been abandoned. Now, research from Erik Storkebaum and Diether Lambrechts, under Peter Carmeliet's direction, has shown the effectiveness of such a treatment on ALS rats. Testing the treatment on rats with a severe form of ALS and on rats with a milder form, the researchers found that, in both groups, the VEGF-treated rats contracted the disease later than the untreated animals, and they continued to live considerably longer.

The researchers also investigated what the optimal technique would be for administering VEGF. An ordinary injection proved to be ineffective. But continuous administration of the VEGF protein - by means of a small pump - directly into the cerebrospinal fluid (the fluid that circulates around the brain and the spinal cord) was quite effective.

New hope for patients

Furthermore, this technique permits a patient-oriented approach by enabling the administered dose of the VEGF protein to be easily controlled. Te
'"/>

Contact: Sooike Stoops
sooike.stoops@vib.be
32-9-244-6611
VIB, Flanders Interuniversity Institute of Biotechnology
29-Nov-2004


Page: 1 2 3

Related biology news :

1. Promising protein may prevent eye damage in premature babies
2. Tailored treatments: Promising designer drug provides new insight into cancer biology
3. Promising antiobesity drug fails to produce clinically meaningful weight loss
4. Promising preclinical results with live attenuated H5N1 vaccines
5. Promising new research on hereditary diseases
6. Promising cell protein may play role in infection and dry eye
7. Promising anti-TB compound finally can be synthesized with ease
8. Promising new preventative treatment option for population of men at high risk of prostate cancer
9. Cooperative science program yields results
10. Delayed treatment of childhood-onset bipolar disorder results in negative outcome in adults
11. Smelling for first time results from knowing abnormalities in congenital loss of smell

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Promising results the battle against incurable ALS muscle disease

(Date:8/19/2014)... have devised a new implantable tissue scaffold coated with ... few weeks. When applied to bone injuries or defects, ... new bone that looks and behaves just like the ... offer a dramatic improvement over the current standard for ... part of the patient,s body a painful process ...
(Date:8/19/2014)... infants born with neonatal abstinence syndrome (NAS) secondary ... time going through withdrawal than others, but the ... and epigenetic (when genes are turned on or ... factors, researchers at Boston University School of Medicine ... first of its kind study to identify some ...
(Date:8/19/2014)... seas during warm phases and became extinct during cold ... a link between marine crocodilian diversity and the evolution ... 140 million years. , The research, led by ... and formerly from the University of Bristol, UK is ... crocodiles are ,cold-blooded, animals that mainly live in fresh ...
Breaking Biology News(10 mins):Engineering new bone growth 2Engineering new bone growth 3In-utero methadone, Subutex exposure could alter gene expression, cause severe Neonatal Abstience Syndrome 2Evolution of marine crocodilians constrained by ocean temperatures 2
(Date:8/19/2014)... 2014 Cellgen Diagnostics ... to fund a corporate lab for its genetic-based ... development is a critical component in the move ... the implementation of personalized medicine – a more ... , Indiegogo contributions will support Cellgen’s intent to ...
(Date:8/19/2014)... , Aug. 19, 2014 ... the addition of the "Spectroscopy Equipment ... report to their offering. ... for Spectroscopy Equipment and Accessories in US$ ... Spectroscopy (UV-Vis spectrophotometers, Raman Spectrometers, NMR-EPR Spectrometers, ...
(Date:8/19/2014)... 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the ... of its Oral Amphotericin B (Oral Amp B) ... conducted by ImmuneCarta®, the immune monitoring business unit ... of Oral Amp B in reactivating latent HIV ... intensive treatment with antiretroviral therapy. ...
(Date:8/18/2014)... /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD), a life sciences ... for advanced microarray diagnostics, today announced it will hold ... 2:00 pm ET.  During the call, ... review of SQI,s recent commercialization progress and then introduce ... recently appointed to the Board of Directors of SQI ...
Breaking Biology Technology:Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 2SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 3
Cached News: